In­novent Bi­o­log­ics sets a biotech record in Chi­na with $260M raise for PhI­II work

With the sub­stan­tial help of the Chi­nese gov­ern­ment, Shang­hai-based In­novent Bi­o­log­ics has lined up a record $260 mil­lion D round de­signed to take its first set of biosim­i­lars through late-stage test­ing as it builds out its man­u­fac­tur­ing op­er­a­tions. And com­pa­ny ex­ecs tell me that it will al­so help con­struct a pipeline of new drugs as In­novent lines up part­ners to mar­ket its ther­a­peu­tics out­side of Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.